Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/STAU1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/STAU1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/STAU1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/STAU1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/STAU1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/STAU1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/STAU1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004852411 | Liver | HCC | positive regulation of viral process | 52/7958 | 65/18723 | 6.70e-10 | 2.11e-08 | 52 |
GO:190390012 | Liver | HCC | regulation of viral life cycle | 94/7958 | 148/18723 | 1.93e-07 | 3.49e-06 | 94 |
GO:004506922 | Liver | HCC | regulation of viral genome replication | 59/7958 | 85/18723 | 4.66e-07 | 7.61e-06 | 59 |
GO:004507021 | Liver | HCC | positive regulation of viral genome replication | 26/7958 | 30/18723 | 7.18e-07 | 1.12e-05 | 26 |
GO:009901021 | Liver | HCC | modification of postsynaptic structure | 13/7958 | 16/18723 | 1.84e-03 | 9.42e-03 | 13 |
GO:009956321 | Liver | HCC | modification of synaptic structure | 16/7958 | 22/18723 | 4.03e-03 | 1.76e-02 | 16 |
GO:001603220 | Oral cavity | OSCC | viral process | 274/7305 | 415/18723 | 2.42e-29 | 1.70e-26 | 274 |
GO:001905820 | Oral cavity | OSCC | viral life cycle | 208/7305 | 317/18723 | 4.59e-22 | 1.00e-19 | 208 |
GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
GO:006219720 | Oral cavity | OSCC | cellular response to chemical stress | 204/7305 | 337/18723 | 6.89e-16 | 5.19e-14 | 204 |
GO:001907920 | Oral cavity | OSCC | viral genome replication | 95/7305 | 131/18723 | 6.35e-15 | 4.02e-13 | 95 |
GO:003459920 | Oral cavity | OSCC | cellular response to oxidative stress | 173/7305 | 288/18723 | 2.90e-13 | 1.43e-11 | 173 |
GO:005079220 | Oral cavity | OSCC | regulation of viral process | 109/7305 | 164/18723 | 8.95e-13 | 4.10e-11 | 109 |
GO:190390020 | Oral cavity | OSCC | regulation of viral life cycle | 97/7305 | 148/18723 | 5.34e-11 | 1.67e-09 | 97 |
GO:004852417 | Oral cavity | OSCC | positive regulation of viral process | 51/7305 | 65/18723 | 9.56e-11 | 2.90e-09 | 51 |
GO:004506917 | Oral cavity | OSCC | regulation of viral genome replication | 62/7305 | 85/18723 | 2.14e-10 | 6.04e-09 | 62 |
GO:00450708 | Oral cavity | OSCC | positive regulation of viral genome replication | 25/7305 | 30/18723 | 8.09e-07 | 1.12e-05 | 25 |
GO:001603228 | Skin | AK | viral process | 96/1910 | 415/18723 | 7.96e-15 | 3.37e-12 | 96 |
GO:001905828 | Skin | AK | viral life cycle | 74/1910 | 317/18723 | 6.21e-12 | 1.27e-09 | 74 |
GO:000697928 | Skin | AK | response to oxidative stress | 86/1910 | 446/18723 | 4.23e-09 | 3.30e-07 | 86 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STAU1 | SNV | Missense_Mutation | | c.1169N>T | p.Ser390Phe | p.S390F | O95793 | protein_coding | deleterious(0.01) | benign(0.11) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
STAU1 | SNV | Missense_Mutation | | c.1362G>A | p.Met454Ile | p.M454I | O95793 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
STAU1 | SNV | Missense_Mutation | rs772776840 | c.1040A>C | p.Asn347Thr | p.N347T | O95793 | protein_coding | tolerated(0.37) | benign(0.18) | TCGA-BH-A0DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
STAU1 | SNV | Missense_Mutation | | c.382C>G | p.Gln128Glu | p.Q128E | O95793 | protein_coding | tolerated(0.25) | benign(0.193) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STAU1 | insertion | Frame_Shift_Ins | novel | c.984_985insCTGAGCTCAGGAGTTCAAGACCAGCCTGGCCAACGTG | p.Thr329LeufsTer71 | p.T329Lfs*71 | O95793 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
STAU1 | insertion | Nonsense_Mutation | novel | c.951_952insTATAGCAATTTATAACTTAGAAAGTT | p.Glu318TyrfsTer5 | p.E318Yfs*5 | O95793 | protein_coding | | | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
STAU1 | SNV | Missense_Mutation | novel | c.471N>C | p.Leu157Phe | p.L157F | O95793 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STAU1 | SNV | Missense_Mutation | | c.47N>T | p.Ser16Leu | p.S16L | O95793 | protein_coding | deleterious_low_confidence(0.03) | benign(0.011) | TCGA-VS-A9UZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
STAU1 | SNV | Missense_Mutation | novel | c.1361T>C | p.Met454Thr | p.M454T | O95793 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
STAU1 | SNV | Missense_Mutation | | c.1580C>A | p.Pro527Gln | p.P527Q | O95793 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR |